Is pemetinib effective for late-stage cholangiocarcinoma?

Pemetinib (Pemazyre) is an oral small molecule inhibitor that specifically targets mutations in the FGFR (fibroblast growth factor receptor) gene. In cholangiocarcinoma, mutations in the FGFR gene are a common phenomenon. By inhibiting these mutations, pemetinib prevents the transformation of cancer cells into normal cells, thereby inhibiting the proliferation and growth of cancer cells.

Multiple clinical trials have confirmed the effectiveness of pemetinib in the treatment of cholangiocarcinoma. For example, in the FIGHT-202 phase II clinical trial, for locally advanced or metastatic patients with poor response to previous treatments, For patients with cholangiocarcinoma, the objective response rate after receiving pemetinib treatment reached 35.5%, and the disease control rate was as high as 82%. This means that more than half of the patients treated with pemetinib had their disease effectively controlled.

In addition to its inhibitory effect on cancer cell proliferation and growth, pemetinib can also significantly prolong patient survival. In a follow-up study of 67 patients, the median overall survival of pemetinib reached 21.1 months, which was significantly improved compared with the historical average survival of patients treated with second- and third-line treatments in the past.

Although pemetinib may cause some side effects, such as nausea, vomiting, fatigue, and diarrhea, these are controllable. In clinical trials, patients generally tolerated pemetinib treatment, and the most common adverse events, such as hyperphosphatemia, were mostly mild to moderate and could be managed by adjusting the dose or treatment regimen.

Pemetinib, as a targeted therapy for cholangiocarcinoma, has shown certain efficacy in patients with advanced cholangiocarcinoma. It effectively controls the disease, prolongs the survival period of patients, and improves the quality of life by inhibiting the mutation of the FGFR gene. However, each patient's response may be different, so before using pemetinib, you should decide whether to use it based on the patient's specific situation and the doctor's advice.